{"filing":{"accession_number":"0001193125-26-391280","cik":"0001831828","ticker":"VERA","company_name":"Vera Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"d32300d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526391280/d32300d8k.htm"},"events":[{"id":33449,"run_id":30755,"accession_number":"0001193125-26-391280","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Vera Therapeutics announced positive final efficacy analysis results for TRUTAKNA in the ORIGIN 3 Phase 3 trial for IgA nephropathy, demonstrating that the drug met all prespecified endpoints including 76% risk reduction in composite kidney disease progression and stabilization of eGFR through 104 weeks. The company plans to submit a supplemental BLA for full approval in Q4 2026 based on these results, with strong early commercial launch momentum reported.","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36898,"accession_number":"0001193125-26-391280","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vera Therapeutics announced positive final efficacy analysis results for TRUTAKNA in the ORIGIN 3 trial, demonstrating that the drug met all prespecified endpoints including stabilization of eGFR and 76% risk reduction in composite kidney disease progression. While this is a significant clinical milestone for a commercial-stage biotech company with an FDA-approved product, it does not fit neatly into the standard 8-K event taxonomy. The disclosure is neither an earnings release (no financial results), nor a material impairment, debt issuance, or other financial event. It is a material operational/clinical development that would affect investor assessment of the company's commercial prospects and regulatory pathway (supplemental BLA submission planned for Q4 2026), making it material but best classified as an operational milestone rather than a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T10:46:43.587483+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36899,"accession_number":"0001193125-26-391280","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vera Therapeutics announced that TRUTAKNA met all prespecified endpoints in the ORIGIN 3 Phase 3 trial for IgA nephropathy, including statistically significant reductions in kidney disease progression (76% risk reduction, p\u003c0.0001) and stabilization of eGFR through 104 weeks. While this is a positive clinical trial result for an already-approved drug, it represents a material operational/commercial milestone—the company plans to submit a supplemental BLA for full approval in Q4 2026 based on these results, and reports strong early commercial launch momentum with over 350 patient start forms in the first ten weeks. This is distinct from an earnings release (which reports financial results) and is best classified as a material operational milestone regarding a key product's clinical validation and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T10:46:43.587483+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36898,"accession_number":"0001193125-26-391280","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vera Therapeutics announced positive final efficacy analysis results for TRUTAKNA in the ORIGIN 3 trial, demonstrating that the drug met all prespecified endpoints including stabilization of eGFR and 76% risk reduction in composite kidney disease progression. While this is a significant clinical milestone for a commercial-stage biotech company with an FDA-approved product, it does not fit neatly into the standard 8-K event taxonomy. The disclosure is neither an earnings release (no financial results), nor a material impairment, debt issuance, or other financial event. It is a material operational/clinical development that would affect investor assessment of the company's commercial prospects and regulatory pathway (supplemental BLA submission planned for Q4 2026), making it material but best classified as an operational milestone rather than a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T10:46:43.587483+00:00","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-09-15"},{"id":36899,"accession_number":"0001193125-26-391280","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vera Therapeutics announced that TRUTAKNA met all prespecified endpoints in the ORIGIN 3 Phase 3 trial for IgA nephropathy, including statistically significant reductions in kidney disease progression (76% risk reduction, p\u003c0.0001) and stabilization of eGFR through 104 weeks. While this is a positive clinical trial result for an already-approved drug, it represents a material operational/commercial milestone—the company plans to submit a supplemental BLA for full approval in Q4 2026 based on these results, and reports strong early commercial launch momentum with over 350 patient start forms in the first ten weeks. This is distinct from an earnings release (which reports financial results) and is best classified as a material operational milestone regarding a key product's clinical validation and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T10:46:43.587483+00:00","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-09-15"}]}